RxDoctor Payments DataLook up a doctor →

Edward Manche, MD

Cornea and External Diseases Specialist · Stanford, CANPI 1992863443

Payments from drug & device makers

$1,595,864in general payments, 2019–2025

Across 225 payments — averaging $7092.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$1.2M
  • Carl Zeiss Meditec, Inc.$141K
  • Alcon Research LLC$84K
  • Novartis$77K
  • Avedro Inc.$49K
  • Glaukos Corporation$32K
  • plus $19K from 8 others
$32,250in research payments, 2019–2025

Across 5 payments — averaging $6450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson Surgical Vision, Inc.$32K

What the payments were for

  • Consulting fees$70,51390%
  • Speaking & faculty fees$5001%
  • Travel & lodging$1,4112%
  • Food & beverage$5,7297%
  • Gifts$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,595,864 in reported general payments places this provider in the 95th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$15,348
Medicare patients
58
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate16$410
MoxifloxacinMoxifloxacin Hcl13$313

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →